AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00578617
Drug: Rate Control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin 0.125mg
Trial: NCT00578617
Drug: Rhythm Control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
DrugBank: Aluminum zirconium trichlorohydrex gly (DB11116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone 450mg
Trial: NCT00578617
Drug: Rhythm control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
DrugBank: Aluminum zirconium trichlorohydrex gly (DB11116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide 200mg
Trial: NCT00960492
Drug: XL184
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules
Trial: NCT00960492
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 75 mg/m2/day given daily with concurrent RT for 6 weeks
Trial: NCT00960492
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 200 mg/m2/day given for 5 consecutive days and repeated every 28 days.
Trial: NCT00960492
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules.
Trial: NCT03387020
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00578617
Drug: Rhythm control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
DrugBank: Aluminum zirconium trichlorohydrex gly (DB11116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 240mg
Trial: NCT03387020
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT00578617
Drug: Rhythm control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
DrugBank: Aluminum zirconium trichlorohydrex gly (DB11116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dofetilide 500mcg
Trial: NCT00578617
Drug: Rhythm control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
DrugBank: Aluminum zirconium trichlorohydrex gly (DB11116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone 200mg
Trial: NCT04236362
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A multi-target receptor tyrosine kinase inhibitor
Trial: NCT00578617
Drug: Rhythm control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
DrugBank: Aluminum zirconium trichlorohydrex gly (DB11116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine 600-900mg
Trial: NCT01028222
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib was provided as 200 mg hard gelatin capsules for oral use.
Trial: NCT01028222
Drug: DTIC
RxNorm normalized name: DTIC
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DTIC was supplied locally as sterile powder for i.v. infusion.
Trial: NCT03979859
Drug: WCK 4873
RxNorm normalized name: Wck 771 free base
DrugBank: Levonadifloxacin (DB16219)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00402467
Drug: Rivaroxaban (BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2.5mg bid
Trial: NCT00402467
Drug: Rivaroxaban, (BAY59-7939)
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg bid
Trial: NCT00402467
Drug: Rivaroxaban, (BAY59-7939)
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg bid
Trial: NCT00402467
Drug: Rivaroxaban, (BAY59-7939)
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20mg bid
Trial: NCT00402467
Drug: Enoxaparine
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg bid
Trial: NCT00863109
Drug: Ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
Trial: NCT00016263
Drug: dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00682565
Drug: CK-1827452 25mg capsule
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg oral immediate release capsule
Trial: NCT02206165
Drug: Candesartan 8mg
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day, 8 weeks
Trial: NCT02206165
Drug: Candesartan 16mg
RxNorm normalized name: CANDESARTAN 16MG/HCTZ 12.5MG TAB
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day, 8 weeks
Trial: NCT02206165
Drug: Amlodipine 5mg
RxNorm normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once a day, 8 weeks
Trial: NCT02206165
Drug: Amlodipine 10mg
RxNorm normalized name: AMLODIPINE 10MG/VALSARTAN 160MG TAB
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once a day, 8 weeks
Trial: NCT00913328
Drug: Montelukast (Singulair)
RxNorm normalized name: montelukast Chewable Tablet [Singulair]
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg tablet once daily
Trial: NCT02251067
Drug: VPI-2690B low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Comparison of different doses of study drug
Trial: NCT00061672
Drug: ABT-510 - Thrombospondin-1 Mimetic
RxNorm normalized name: ABT-925
DrugBank: ABT-510 (DB05434)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01219855
Drug: Cohort 1 Matching Sugar Capsule
RxNorm normalized name: Sugar
DrugBank: 1-3 Sugar Ring of Pentamannosyl 6-Phosphate (DB02755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules given once daily for 42 days.
Trial: NCT02593942
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75-200 mcg/kg/min infusion
Trial: NCT03930602
Drug: BMS-986165
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive BMS-986165.
Trial: NCT01219855
Drug: Cohort 2 CTAP101 Capsules - 30µg
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30µg of CTAP101 capsules given once daily for 42 days.
Trial: NCT01219855
Drug: Cohort 2 Matching Sugar Capsule
RxNorm normalized name: Sugar
DrugBank: 1-3 Sugar Ring of Pentamannosyl 6-Phosphate (DB02755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules given once daily for 42 days.
Trial: NCT00516711
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02251067
Drug: VPI-2690B medium dose
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different doses of study drug
Trial: NCT04202952
Drug: Sofosbuvir Tablet
RxNorm normalized name: Sofosbuvir Tablets
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered orally once daily
Trial: NCT00003108
Drug: bryostatin 1
RxNorm normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003108
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02251067
Drug: VPI-2690B high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different doses of study drug
Trial: NCT00610714
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous injection
Trial: NCT03930602
Drug: Fluvoxamine
RxNorm normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive fluvoxamine.
Trial: NCT02938507
Drug: Formulation 1 solabegron
RxNorm normalized name: Solabegron
DrugBank: Solabegron (DB06190)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02938507
Drug: Formulation 2 solabegron
RxNorm normalized name: Hep B, unspecified formulation
DrugBank: Solabegron (DB06190)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02343744
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary.
Trial: NCT02646670
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: - In the first group will be held three applications of intravitreal ranibizumab 0.1 ml, with one application every month and follow up with Optical Coherence Tomography
Trial: NCT03213834
Drug: tPA
RxNorm normalized name: tPA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tPA administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
Trial: NCT02646670
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: - In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml, with one application each month followed by monitoring with Optical Coherence Tomography
Trial: NCT02646670
Drug: Ranibizumab and Aflibercept
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: - The third group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
Trial: NCT02646670
Drug: Aflibercept and ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: - In the fourth group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
Trial: NCT02121444
Drug: Interferon beta-1b (Betaferon, BAY 86-5046)
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02280486
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg/d
Trial: NCT02280486
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg/d, up titrated 1mg if FPG \>6.1 mmol/L (110mg/dL) till 6 mg
Trial: NCT01574937
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 28 day cycle
Trial: NCT01574937
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 day cycle
Trial: NCT01248585
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days
Trial: NCT02682082
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoscopic ultrasound-guided celiax plexus neurolysis w/wo Bupivacaine
Trial: NCT01756404
Drug: Canagliflozin (JNJ-28431754)
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.
Trial: NCT02956317
Drug: STP705
RxNorm normalized name: STP705 (small interfering RNA (siRNA) therapeutic directed against transforming growth factor-beta 1 (TGF-beta 1) and cyclo-oxygenase-2 (COX-2))
DrugBank: Cotsiranib (DB18404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.
Trial: NCT01772732
Drug: Simotinib Hydrochloride
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02596035
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00776698
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7.5mg/kg every 3 weeks for 3 cycles (cohort 1) or 15mg/kg every 3 weeks for 3 cycles (cohort 2). Preferred dose every 3 weeks for 9 cycles (cohort 3).
Trial: NCT00776698
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80mg/m2 iv every 3 weeks for 3 cycles
Trial: NCT00776698
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100mg/m2 iv for 3 consecutive days, every 3 weeks for 3 cycles
Trial: NCT00610714
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous infusion
Trial: NCT02799498
Drug: Etanercept (ENBREL®)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
Trial: NCT04623840
Drug: Tadalafil 5Mg Tab
RxNorm normalized name: TADALAFIL 5MG TAB
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, for eight weeks
Trial: NCT03704909
Drug: Adrenaline
RxNorm normalized name: Adrenaline
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i.v bolus of adrenaline 0.15µg/Kg rescue boluses of adrenaline 0.15µg/Kg
Trial: NCT03704909
Drug: Ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i.v bolus of Ephedrine 0.1mg/Kg rescue boluses of Ephedrine 0.1mg/Kg
Trial: NCT00371566
Drug: Lapatinib oral tablets
RxNorm normalized name: lapatinib Oral Tablet
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03261570
Drug: Pyridostigmine
RxNorm normalized name: Pyridostigmine
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60mg by mouth
Trial: NCT03261570
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 (500mcg) by mouth
Trial: NCT02233023
Drug: Pramipexole
RxNorm normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04441255
Drug: TAK-788
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-788 Capsule.
Trial: NCT02733250
Drug: Nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100mg/m2 IV Day 1, 8 and 15 of every 21 day cycles
Trial: NCT01129778
Drug: Zegerid (proton pump inhibitor)
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00517933
Drug: Sildenafil Citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (20mg 3 times a day \[TID\] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)
Trial: NCT00215592
Drug: Zonegran
RxNorm normalized name: Zonegran
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01839812
Drug: Cosyntropin
RxNorm normalized name: Cosyntropin
DrugBank: Tetracosactide (DB01284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A cosyntropin stimulation test is administered to each patient at 3 time points during the study to evaluate adrenal response.
Trial: NCT01835899
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medium dose 1 powder for oral solution
Trial: NCT01835899
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medium dose 2 powder for oral solution
Trial: NCT01835899
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose 1 powder for oral solution
Trial: NCT00858637
Drug: MCI-196
RxNorm normalized name: kaolin 196 MG/ML
DrugBank: Kaolin (DB01575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
Trial: NCT00604695
Drug: Tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of IV tenecteplase.
Trial: NCT00318370
Drug: Farletuzumab
RxNorm normalized name: Farletuzumab
DrugBank: Farletuzumab (DB05595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly Farletuzumab infusions Dose dependent on dosing group
Trial: NCT01589393
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 30 mg subcutaneously twice daily for six doses starting 36-48 hours post traumatic injury.
Trial: NCT02448914
Drug: Duodopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive Duodopa. Treatment order is determined by randomization.
Trial: NCT01399840
Drug: BMN 673
RxNorm normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule with multiple dosage forms given once daily
Trial: NCT00133172
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00133172
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT00133172
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00608842
Drug: Deoxycholic Acid Injection
RxNorm normalized name: deoxycholic acid Injection
DrugBank: Deoxycholic acid (DB03619)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered via intralipomal injection.
Trial: NCT00434109
Drug: Sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib malate (Sutent) at a dose of 37.5mg will be administered orally once daily on days 1-28 in a 42-day cycle. Treatment with Sutent will begin no sooner than seven days after the first hepatic artery embolization. Subsequent embolizations (if necessary) will be scheduled during scheduled Sutent treatment breaks. No fewer than seven days shall separate treatment with Sutent and scheduling of hepatic artery embolizations.
Trial: NCT00308971
Drug: Alpha, gamma, beta, and delta (mixed) tocopherols
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: approximately 666 IU daily (1 pill) for 4 months
Trial: NCT00308971
Drug: alpha lipoic acid
RxNorm normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg daily (2 pills 300 mg each) for 4 months
Trial: NCT02699125
Drug: Guanfacine
RxNorm normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.